Revolution Medicines (RVMD) Other Non-Current Liabilities (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Other Non-Current Liabilities of $6.9 million for Q1 2026, up 817.2% year-over-year from $750000.0 in Q1 2025, and down 62.91% quarter-over-quarter from $18.5 million in Q4 2025.
Revolution Medicines (RVMD) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Revolution Medicines' Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 817.2% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (up 817.2% YoY), while the FY2025 annual figure was $18.5 million, up 2668.06% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $6.9 million, down from $18.5 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $18.5 million in Q4 2025, with the low at $219000.0 in Q2 2022.
- The 5-year median for Other Non-Current Liabilities is $1.5 million (2023), against an average of $3.0 million.
- Peak annual rise in Other Non-Current Liabilities reached 2668.06% in 2025, while the deepest fall reached 76.24% in 2025.
- Revolution Medicines' Other Non-Current Liabilities stood at $301000.0 in 2022, then jumped by 384.39% to $1.5 million in 2023, then tumbled by 54.05% to $670000.0 in 2024, then surged by 2668.06% to $18.5 million in 2025, then sank by 62.91% to $6.9 million in 2026.
- Business Quant data shows RVMD's Other Non-Current Liabilities at $6.9 million in Q1 2026, $18.5 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 185.25 Mn |
| Mar 31, 2026 | 6.88 Mn |
| Dec 31, 2025 | 18.55 Mn |
| Sep 30, 2025 | 2.48 Mn |
| Jun 30, 2025 | 7.20 Mn |
| Mar 31, 2025 | 750,000.00 |
| Dec 31, 2024 | 670,000.00 |
| Sep 30, 2024 | 2.76 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 3.16 Mn |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 982,000.00 |
| Jun 30, 2023 | 252,000.00 |
| Mar 31, 2023 | 1.69 Mn |
| Dec 31, 2022 | 301,000.00 |
| Sep 30, 2022 | 471,000.00 |
| Jun 30, 2022 | 219,000.00 |
| Mar 31, 2022 | 1.63 Mn |
| Dec 31, 2021 | 634,000.00 |
| Sep 30, 2021 | 932,000.00 |